Cannabinoid Biosynthesis Market Forecast with Size and Share Analysis 2026 to 2035
What is Cannabinoid Biosynthesis Market Size?
Global Cannabinoid Biosynthesis Market Size was valued at USD 2.57 Bn in 2025 and is predicted to reach USD 9.67 Bn by 2035 at a 14.3% CAGR during the forecast period for 2026 to 2035
Cannabinoid Biosynthesis Market Size, Share & Trends Analysis Report By Type (Balanced THC and CBD, Cannabidiol Dominant, THC Dominant, and Others), By Application Type (Pain Management, Anxiety Management, Appetite Stimulation, and Nausea Management), By Region, And By Segment Forecasts, 2026 to 2035
Cannabinoid Biosynthesis Market Key Takeaways:
|
Cannabinoids found in the cannabis sativa plant. The plant contains about 480 distinct chemicals, including 66 cannabinoids. Biosynthesis is the process by which cannabinoids are produced. Enzymatic reactions using substances derived from either natural or synthetic sources are carried out in controlled environments in laboratories to carry out the process. The market for pharmaceuticals derived from cannabinoids is being propelled by the potential medicinal benefits of these compounds, which include the alleviation of chemotherapy-related symptoms, chronic pain, and muscular spasms. The market for cannabinoid biosynthesis is expected to grow as more is learned about its therapeutic effects through research. Products derived from cannabinoids have seen a surge in demand due to the popularity of alternative medicine is growing and also the growing preference for natural and plant-based healthcare solutions. Furthermore, products derived from cannabinoids are in high demand due to the global trend toward legalizing cannabis. The need for biosynthetic cannabinoids is predicted to rise as the usage of medicinal cannabis, and its derivatives becomes legal in more nations.
However, the market growth is hampered by the lack of awareness of the safety as well as health of the cannabinoid biosynthesis market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity cannabinoid biosynthesis. Cannabinoid biosynthesis is still in its infancy in comparison to more established ways of cannabinoid manufacturing, which poses problems in terms of funding for research and development. Potentially stunting market expansion is the current state of knowledge on the safety and long-term impacts of biosynthetic cannabinoids.
The widespread prejudice and discrimination that surrounds cannabis usage, especially when used medicinally, can have an impact on how widely used and accepted cannabinoid products are. Market expansion could be stunted if consumers and healthcare providers are misled about the safety and effectiveness of cannabis. Several cannabinoid-based products, including cannabinol, cannabigerol, and cannabidiolic acid, were affected by the COVID-19 pandemic. The early months of the epidemic saw panic buying, which further reduced product appeal, priority, and sales.
Competitive Landscape
Some Major Key Players In The Cannabinoid Biosynthesis Market:
- Hyasynth Biologicals
- Amyris Inc
- Demetrix
- Jazz Pharmaceuticals PLC
- Lygos,
- Renew Biopharma
- CB Therapeutics
- Canopy Growth Corp
- Zymergen Inc
- Cronos Group Inc.
- Creo
- Constellation Brands Inc
- Evolva Holding SA
- Willow Biosciences Inc
- InMed Pharmaceuticals
- Purisys
- Others
Market Segmentation:
The cannabinoid biosynthesis market is segmented based on type and application. Based on type, the market is segmented into balanced THC and CBD, cannabidiol-dominant, THC-dominant, and others. The application segment is segmented into pain management, anxiety management, appetite stimulation, and nausea management.
Based On The Application, The Anxiety Management Segment Is Accounted As A Major Contributor To The Cannabinoid Biosynthesis Market.
The anxiety management cannabinoid biosynthesis market will hold a major global market share in 2022. The anxiety management subsegment is likely to grow faster than any other. There has been a rise in the usage of cannabinoids as an alternative treatment option for stress and anxiety, with CBD, in particular, showing promise in this regard. This subsegment of the cannabinoid biosynthesis market has been expanding due to rising customer knowledge of cannabis' medicinal properties and the need for safe, effective alternatives to pharmaceutical anxiety treatments.
THC Dominant Segment To Witness Growth At A Rapid Rate.
The THC-dominant industry makes up the bulk of cannabinoid biosynthesis usage because of its euphoric properties; tetrahydrocannabinol, or THC, is used both recreationally and medicinally, particularly for the treatment of nausea and chronic pain. The THC-dominant segment of the cannabinoid biosynthesis market is experiencing rapid expansion because of the increasing legalization of cannabis in various places and the increasing adoption of THC-based products, especially in countries like the US, Germany, the UK, China, and India.
In The Region, The North American Cannabinoid Biosynthesis Market Holds A Significant Revenue Share.
The North American cannabinoid biosynthesis market is expected to register the maximum market share in revenue in the near future. It can be attributed to the fact that many states have passed legislation decriminalizing cannabis for both recreational and medical use. The result is a strong market for goods derived from cannabis.
In addition, Asia Pacific is estimated to grow rapidly in the global cannabinoid biosynthesis market because of the increasing legality of cannabinoid-based medicines, the rising popularity of medical cannabis, and the diversified healthcare demands of the growing population.
Recent Developments:
- In May 2022, Evonik and Demetrix formed a partnership to enhance the presence of cannabinoids in the personal care market. The partnership's inaugural product, cannabigerol (CBG), was introduced to global markets in 2022.
- In Nov 2020, Renew Biopharma made an announcement stating that Algae-C Inc. has obtained legal permission to utilize Renew's specially designed enzymes for the production of cannabis in microalgae. Renew's collection of modified enzymes facilitated the increased manufacturing of cannabinoids and cannabinoid derivatives.
Cannabinoid Biosynthesis Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 2.57 Bn |
| Revenue Forecast In 2035 | USD 9.67 Bn |
| Growth Rate CAGR | CAGR of 14.3% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, Application Type |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Hyasynth Biologicals, Amyris Inc, Demetrix, Jazz Pharmaceuticals PLC, Lygos, Renew Biopharma, CB Therapeutics, Canopy Growth Corp, Zymergen Inc, Cronos Group Inc., Creo, Constellation Brands Inc, Evolva Holding SA, Willow Biosciences Inc, InMed Pharmaceuticals, Purisys and Others. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation Of Cannabinoid Biosynthesis Market :
Cannabinoid Biosynthesis Market, By Type-
- Balanced THC and CBD
- Cannabidiol Dominant
- THC Dominant
- Others
Cannabinoid Biosynthesis Market, By Application Type-
- Pain Management
- Anxiety Management
- Appetite Stimulation
- Nausea Management
Cannabinoid Biosynthesis Market, By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Cannabinoid Biosynthesis Market Size is predicted to witness a 14.3% CAGR during the forecast period for 2026 to 2035
Hyasynth Biologicals, Amyris Inc, Demetrix, Jazz Pharmaceuticals PLC, Lygos, Renew Biopharma, CB Therapeutics, Canopy Growth Corp, Zymergen Inc, Cronos Group Inc., Creo, Constellation Brands Inc, Evolva Holding SA, Willow Biosciences Inc, InMed Pharmaceuticals, Purisys and Others.
Type and Application are the key segments of the Cannabinoid Biosynthesis Market.
North American region is leading the Cannabinoid Biosynthesis Market.
Cannabinoid Biosynthesis Market Size was valued at USD 2.57 Bn in 2025 and is predicted to reach USD 9.67 Bn by 2035